Recurrence and mortality after breast-conserving surgery without radiation.
Breast cancer
breast-conserving therapy
death
radiation therapy
recurrence
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
entrez:
4
1
2020
pubmed:
4
1
2020
medline:
17
7
2020
Statut:
ppublish
Résumé
Breast-conserving surgery (bcs) and radiation therapy (rt) are the standard of care for early breast cancer; studies have demonstrated that adjuvant rt confers a protective effect with respect to recurrence, although no randomized trials have shown a survival benefit. This retrospective cohort study used Ontario data linked through ices to examine patients treated for breast cancer between 1 April 2007 and 31 March 2014. The primary outcome was death or recurrence. Outcomes were compared between patients who did and did not receive rt. The total cohort size was 26,279. The hazard ratios (hrs) for various outcomes were significantly higher for patients who did not receive rt than for patients who did: recurrence or death combined [hr: 2.49; 95% confidence interval (ci): 2.25 to 2.75], recurrence (hr: 2.33; 95% ci: 1.91 to 2.84), and death (hr: 2.28; 95% ci: 2.03 to 2.56). The hr for death was 1.81 (95% ci: 1.65 to 1.99) for patients having stage ii cancer compared with those having stage i disease. The hr for death was 1.97 (95% ci: 1.74 to 2.22) for patients having high comorbidity compared with those having little comorbidity. Adjuvant rt carries a protective effect with respect to recurrence and survival in patients with early-stage breast cancer. That survival benefit has not been appreciated in previous randomized trials and underscores the importance of rt as a component of breast cancer treatment.
Sections du résumé
Background
Breast-conserving surgery (bcs) and radiation therapy (rt) are the standard of care for early breast cancer; studies have demonstrated that adjuvant rt confers a protective effect with respect to recurrence, although no randomized trials have shown a survival benefit.
Methods
This retrospective cohort study used Ontario data linked through ices to examine patients treated for breast cancer between 1 April 2007 and 31 March 2014. The primary outcome was death or recurrence. Outcomes were compared between patients who did and did not receive rt.
Results
The total cohort size was 26,279. The hazard ratios (hrs) for various outcomes were significantly higher for patients who did not receive rt than for patients who did: recurrence or death combined [hr: 2.49; 95% confidence interval (ci): 2.25 to 2.75], recurrence (hr: 2.33; 95% ci: 1.91 to 2.84), and death (hr: 2.28; 95% ci: 2.03 to 2.56). The hr for death was 1.81 (95% ci: 1.65 to 1.99) for patients having stage ii cancer compared with those having stage i disease. The hr for death was 1.97 (95% ci: 1.74 to 2.22) for patients having high comorbidity compared with those having little comorbidity.
Conclusions
Adjuvant rt carries a protective effect with respect to recurrence and survival in patients with early-stage breast cancer. That survival benefit has not been appreciated in previous randomized trials and underscores the importance of rt as a component of breast cancer treatment.
Identifiants
pubmed: 31896936
doi: 10.3747/co.26.5225
pii: conc-26-380
pmc: PMC6927776
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-388Informations de copyright
2019 Multimed Inc.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
Références
J Natl Cancer Inst Monogr. 1992;(11):19-25
pubmed: 1627427
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Med Care. 2013 Apr;51(4):e22-6
pubmed: 21979370
Arch Gerontol Geriatr. 2012 Sep-Oct;55(2):283-8
pubmed: 22037244
Clin Breast Cancer. 2018 Apr;18(2):e179-e185
pubmed: 28941977
N Engl J Med. 2004 Sep 2;351(10):963-70
pubmed: 15342804
Breast Cancer Res Treat. 2018 Jul;170(2):405-414
pubmed: 29569018
N Engl J Med. 1995 Apr 6;332(14):907-11
pubmed: 7877647
J Clin Oncol. 1996 May;14(5):1558-64
pubmed: 8622072
N Engl J Med. 1995 Nov 30;333(22):1456-61
pubmed: 7477145
J Natl Cancer Inst. 2004 Jan 21;96(2):115-21
pubmed: 14734701
JAMA Oncol. 2018 Aug 1;4(8):e180194
pubmed: 29800965
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819
Stat Med. 2010 Sep 10;29(20):2137-48
pubmed: 20108233
Cancer. 2008 Dec 1;113(11):3108-15
pubmed: 18932243
J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50
pubmed: 10904087
J Clin Oncol. 2004 May 1;22(9):1630-7
pubmed: 15117985
BMJ. 1999 Dec 4;319(7223):1492-5
pubmed: 10582940
Cancer. 2003 Aug 15;98(4):697-702
pubmed: 12910512
Ann Intern Med. 2006 Nov 7;145(9):637-45
pubmed: 17088576
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Cancer. 2011 Jun 15;117(12):2590-8
pubmed: 21656737
Curr Oncol. 2018 Dec;25(6):e545-e552
pubmed: 30607122
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
J Clin Oncol. 2014 Mar 10;32(8):791-7
pubmed: 24493730
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
JAMA Oncol. 2018 Aug 1;4(8):e180163
pubmed: 29800954
J Am Coll Surg. 2008 Jan;206(1):66-75
pubmed: 18155570
Eur J Cancer. 1995 Sep;31A(10):1574-9
pubmed: 7488404